董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kinyip Gabriel Leung | 男 | Independent Director | 63 | 0.0010万美元 | 未持股 | 2025-12-01 |
| William A. Vernon | 男 | Independent Director | 69 | 23.89万美元 | 未持股 | 2025-12-01 |
| Martin J. Madden | 男 | Independent Director | 64 | 19.32万美元 | 未持股 | 2025-12-01 |
| Timothy Scannell | 男 | Independent Director | 61 | 未披露 | 未持股 | 2025-12-01 |
| William F. Doyle | 男 | Executive Chairman and Director | 62 | 2377.46万美元 | 未持股 | 2025-12-01 |
| David Hung | 男 | Independent Director | 67 | 未披露 | 未持股 | 2025-12-01 |
| Allyson Ocean | 女 | Independent Director | 53 | 未披露 | 未持股 | 2025-12-01 |
| Kristin Stafford | 女 | Independent Director | 43 | 未披露 | 未持股 | 2025-12-01 |
| Jeryl Hilleman | 女 | Independent Director | 67 | 未披露 | 未持股 | 2025-12-01 |
| David Hung | 男 | Independent Director | 68 | 未披露 | 未持股 | 2025-12-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Nicolas Leupin | 男 | Chief Medical Officer | 51 | 未披露 | 未持股 | 2025-12-01 |
| Barak Ben Arye | 男 | General Counsel | 49 | 未披露 | 未持股 | 2025-12-01 |
| Francis Leonard | 男 | Executive Vice President, President Novocure Oncology | 45 | 未披露 | 未持股 | 2025-12-01 |
| Mukund Paravasthu | 男 | Chief Operating Officer | 55 | 未披露 | 未持股 | 2025-12-01 |
| Michael Puri | 男 | Chief Human Resources Officer | 55 | 未披露 | 未持股 | 2025-12-01 |
| Uri Weinberg | 男 | Chief Innovation Officer | 47 | 未披露 | 未持股 | 2025-12-01 |
| Francis Leonard | 男 | President and Chief Executive Officer | 46 | 未披露 | 未持股 | 2025-12-01 |
| Christoph Brackmann | 男 | Chief Financial Officer | 51 | 未披露 | 未持股 | 2025-12-01 |
董事简历
中英对照 | 中文 | 英文- Kinyip Gabriel Leung
-
Kinyip Gabriel Leung，2011年至2016年担任Novocure的董事会副主席和员工，负责协调Novocure的全球商业运营。2003年至2010年，他在专业制药公司OSI Pharmaceuticals，Inc.（简称“OSI”）工作，之后被Astellas Pharma Inc.收购，最后担任OSI执行副总裁和OSI肿瘤学和糖尿病业务总裁。在任职OSI之前，1999-2003年，Leung先生在全球制药和医疗保健公司Pharmacia Corporation担任全球处方业务的集团副总裁。从1991年到1999年，Leung先生在Bristol-Myers Squibb Company担任高管，该公司是一家全球性的制药和医疗保健公司。
Kinyip Gabriel Leung,was the Vice Chairman of Board and an employee of Novocure from 2011 to 2016, coordinating Novocure's global commercial operations. From 2003 to 2010, he worked for OSI Pharmaceuticals, Inc. ("OSI"), a specialty pharmaceutical company, prior to its acquisition by Astellas Pharma Inc., last serving as Executive Vice President of OSI and the President of OSI's Oncology and Diabetes Business. Prior to his tenure at OSI, from 1999 to 2003, Mr. Leung served as Group Vice President of the Global Prescription Business at Pharmacia Corporation, a global pharmaceutical and healthcare company. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company. - Kinyip Gabriel Leung，2011年至2016年担任Novocure的董事会副主席和员工，负责协调Novocure的全球商业运营。2003年至2010年，他在专业制药公司OSI Pharmaceuticals，Inc.（简称“OSI”）工作，之后被Astellas Pharma Inc.收购，最后担任OSI执行副总裁和OSI肿瘤学和糖尿病业务总裁。在任职OSI之前，1999-2003年，Leung先生在全球制药和医疗保健公司Pharmacia Corporation担任全球处方业务的集团副总裁。从1991年到1999年，Leung先生在Bristol-Myers Squibb Company担任高管，该公司是一家全球性的制药和医疗保健公司。
- Kinyip Gabriel Leung,was the Vice Chairman of Board and an employee of Novocure from 2011 to 2016, coordinating Novocure's global commercial operations. From 2003 to 2010, he worked for OSI Pharmaceuticals, Inc. ("OSI"), a specialty pharmaceutical company, prior to its acquisition by Astellas Pharma Inc., last serving as Executive Vice President of OSI and the President of OSI's Oncology and Diabetes Business. Prior to his tenure at OSI, from 1999 to 2003, Mr. Leung served as Group Vice President of the Global Prescription Business at Pharmacia Corporation, a global pharmaceutical and healthcare company. From 1991 to 1999, Mr. Leung was an executive at Bristol-Myers Squibb Company, a global pharmaceutical and healthcare company.
- William A. Vernon
-
William A. Vernon在2012年至2014年期间担任食品公司Kraft Foods Group, Inc.的首席执行官，并在2015年5月之前担任该公司的高级顾问。2009年至2011年，Vernon先生担任Kraft Foods North America总裁和Kraft Foods执行副总裁。从2006年到2009年，Vernon先生担任私募股权公司Ripplewood Holdings的医疗保健行业合伙人。从1982年到2006年，Vernon先生在Johnson & Johnson担任过多个职务。他于2004年至2005年担任骨科产品和服务提供商DePuy Orthopaedics的公司集团主席，于2001年至2004年担任生物技术公司Centocor的总裁，于1999年至2001年担任OTC和营养品公司McNeil Consumer Pharmaceuticals and Nutritionals，Worldwide的总裁，并于1995年至1999年担任OTC疗法公司Johnson & Johnson-Merck Joint Venture的总裁。
William A. Vernon served as the Chief Executive Officer of Kraft Foods Group, Inc., a food products company, from 2012 to 2014 and also served as its Senior Advisor through May 2015. From 2009 to 2011, Mr. Vernon served as the President of Kraft Foods North America and an Executive Vice President of Kraft Foods. From 2006 to 2009, Mr. Vernon served as the healthcare industry partner for Ripplewood Holdings, a private equity firm. From 1982 to 2006, Mr. Vernon held various roles at Johnson & Johnson. He served as company Group Chairman of DePuy Orthopaedics, a provider of orthopedic products and services, from 2004 to 2005, President of Centocor, a biotechnology company, from 2001 to 2004, President of McNeil Consumer Pharmaceuticals and Nutritionals, Worldwide, an OTC and nutritional products company, from 1999 to 2001 and President of The Johnson & Johnson-Merck Joint Venture, an OTC remedies company, from 1995 to 1999. - William A. Vernon在2012年至2014年期间担任食品公司Kraft Foods Group, Inc.的首席执行官，并在2015年5月之前担任该公司的高级顾问。2009年至2011年，Vernon先生担任Kraft Foods North America总裁和Kraft Foods执行副总裁。从2006年到2009年，Vernon先生担任私募股权公司Ripplewood Holdings的医疗保健行业合伙人。从1982年到2006年，Vernon先生在Johnson & Johnson担任过多个职务。他于2004年至2005年担任骨科产品和服务提供商DePuy Orthopaedics的公司集团主席，于2001年至2004年担任生物技术公司Centocor的总裁，于1999年至2001年担任OTC和营养品公司McNeil Consumer Pharmaceuticals and Nutritionals，Worldwide的总裁，并于1995年至1999年担任OTC疗法公司Johnson & Johnson-Merck Joint Venture的总裁。
- William A. Vernon served as the Chief Executive Officer of Kraft Foods Group, Inc., a food products company, from 2012 to 2014 and also served as its Senior Advisor through May 2015. From 2009 to 2011, Mr. Vernon served as the President of Kraft Foods North America and an Executive Vice President of Kraft Foods. From 2006 to 2009, Mr. Vernon served as the healthcare industry partner for Ripplewood Holdings, a private equity firm. From 1982 to 2006, Mr. Vernon held various roles at Johnson & Johnson. He served as company Group Chairman of DePuy Orthopaedics, a provider of orthopedic products and services, from 2004 to 2005, President of Centocor, a biotechnology company, from 2001 to 2004, President of McNeil Consumer Pharmaceuticals and Nutritionals, Worldwide, an OTC and nutritional products company, from 1999 to 2001 and President of The Johnson & Johnson-Merck Joint Venture, an OTC remedies company, from 1995 to 1999.
- Martin J. Madden
-
MartinJ.Madden，马登于1986年至2017年1月在强生公司工作了30年，最近退休，2016年2月至2017年1月，他担任Vice President新产品开发Vice President研究与开发DePuy-Synthes and Vice President Medical Device研发转型，2015年7月至2016年2月担任医疗器械，2012年1月至2015年7月担任Vice President研发全球外科集团。在他职业生涯的早期，Madden先生是一名医疗设备工程师和创新者，是跨职能团队的领导者，负责孵化、开发和推出新产品。马登先生以优异的成绩毕业于哥伦比亚大学的MBA课程。他以优异成绩毕业于卡内基-梅隆大学（Carnegie-Mellon University），在那里他获得了机械工程硕士学位，并以优异成绩毕业于代顿大学（University of Dayton），自2017年以来获得了机械工程学士学位.Microbot MedicalInc.。
Martin J. Madden,retired after a 30-year career at Johnson & Johnson (1986 to January 2017), where he served as Vice President Research and Development of DePuy-Synthes and Vice President Medical Device R&D transformation from February 2016 to January 2017, as Vice President New Product Development, Medical Devices from July 2015 to February 2016, and as Vice president R&D Global Surgery Group from January 2012 to July 2015. Earlier in his career, Mr. Madden was a medical device engineer and innovator, and a leader of cross-functional teams charged with incubating, developing, and launching new products. - MartinJ.Madden，马登于1986年至2017年1月在强生公司工作了30年，最近退休，2016年2月至2017年1月，他担任Vice President新产品开发Vice President研究与开发DePuy-Synthes and Vice President Medical Device研发转型，2015年7月至2016年2月担任医疗器械，2012年1月至2015年7月担任Vice President研发全球外科集团。在他职业生涯的早期，Madden先生是一名医疗设备工程师和创新者，是跨职能团队的领导者，负责孵化、开发和推出新产品。马登先生以优异的成绩毕业于哥伦比亚大学的MBA课程。他以优异成绩毕业于卡内基-梅隆大学（Carnegie-Mellon University），在那里他获得了机械工程硕士学位，并以优异成绩毕业于代顿大学（University of Dayton），自2017年以来获得了机械工程学士学位.Microbot MedicalInc.。
- Martin J. Madden,retired after a 30-year career at Johnson & Johnson (1986 to January 2017), where he served as Vice President Research and Development of DePuy-Synthes and Vice President Medical Device R&D transformation from February 2016 to January 2017, as Vice President New Product Development, Medical Devices from July 2015 to February 2016, and as Vice president R&D Global Surgery Group from January 2012 to July 2015. Earlier in his career, Mr. Madden was a medical device engineer and innovator, and a leader of cross-functional teams charged with incubating, developing, and launching new products.
- Timothy Scannell
-
Timothy Scannell于2022年3月被任命为公司董事会成员。自2021年10月起，Scannell先生担任Stryker的执行顾问，Stryker是世界领先的医疗技术公司之一。他在Stryker的职业生涯长达30多年，在此期间，他担任过多个领导职务，包括2018年8月至2021年10月担任总裁兼首席运营官，2019年1月至2018年7月担任MedSurg & Neurotechnology集团总裁。Scannell先生还担任Insulet Corporation董事会主席以及Novocure和Collagen Matrix的董事会成员。Scannell先生拥有丰富的战略、销售和营销以及运营技能和经验，在交付顶级成果方面有着良好的记录。Scannell先生在圣母大学获得工商管理学士学位和工商管理硕士学位。
Timothy Scannell,was appointed to the Company's board of directors in March 2022. Mr. Scannell had a 30+ year career at Stryker, one of the world's leading medical technology companies, during which he has held several leadership roles, including serving as President and Chief Operating Officer from August 2018 to October 2021, and as Group President of MedSurg & Neurotechnology from January 2019 to July 2018. Mr. Scannell also serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Regenity Biosciences. Mr. Scannell brings extensive strategic, sales and marketing, and operational skills and experience, and a track record of delivering top tier results. Mr. Scannell earned Bachelor of Business Administration and Master of Business Administration degrees from the University of Notre Dame. - Timothy Scannell于2022年3月被任命为公司董事会成员。自2021年10月起，Scannell先生担任Stryker的执行顾问，Stryker是世界领先的医疗技术公司之一。他在Stryker的职业生涯长达30多年，在此期间，他担任过多个领导职务，包括2018年8月至2021年10月担任总裁兼首席运营官，2019年1月至2018年7月担任MedSurg & Neurotechnology集团总裁。Scannell先生还担任Insulet Corporation董事会主席以及Novocure和Collagen Matrix的董事会成员。Scannell先生拥有丰富的战略、销售和营销以及运营技能和经验，在交付顶级成果方面有着良好的记录。Scannell先生在圣母大学获得工商管理学士学位和工商管理硕士学位。
- Timothy Scannell,was appointed to the Company's board of directors in March 2022. Mr. Scannell had a 30+ year career at Stryker, one of the world's leading medical technology companies, during which he has held several leadership roles, including serving as President and Chief Operating Officer from August 2018 to October 2021, and as Group President of MedSurg & Neurotechnology from January 2019 to July 2018. Mr. Scannell also serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Regenity Biosciences. Mr. Scannell brings extensive strategic, sales and marketing, and operational skills and experience, and a track record of delivering top tier results. Mr. Scannell earned Bachelor of Business Administration and Master of Business Administration degrees from the University of Notre Dame.
- William F. Doyle
-
William F. Doyle，自交易完成以来，他一直担任ProKidney Corp. GP Limited（“GP”）（“GP董事会”）的董事会成员。Doyle先生自2022年1月起担任ProKidney GP Limited（“Legacy GP”）（“Legacy GP董事会”）的董事会成员，并自2022年1月起担任ProKidney（前身为RegenMed （Cayman） Ltd. （d/b/a inRegen））（“ProKidney- ky”）（“ProKidney- ky董事会”）的董事会成员。他自2016年5月起担任NovoCure Limited（Nasdaq：NVCR）的执行主席，这是一家商业阶段的肿瘤学公司，目前正在开发肿瘤治疗领域，一种实体肿瘤癌症的新疗法（“NovoCure”），自2004年2月起担任NovoCure董事会成员。2002年6月以来，他一直担任WFD Ventures LLC（他共同创立的私人风险投资公司）的董事总经理。在此之前，他是Johnson & Johnson的医疗器械和诊断集团运营委员会的成员，从1994年到1999年担任许可和收购副总裁。在Johnson & Johnson任职期间，Doyle先生也是Biosense-Webster, Inc.的全球总裁，Johnson & Johnson Development Corporation （Johnson & Johnson的风险投资子公司）的董事会成员。Doyle先生自2020年10月起担任Elanco Animal Health, Inc.（纽约证券交易所代码：ELAN）的董事会成员，Elanco Animal Health, Inc.是动物健康领域的全球领导者，致力于创新和提供产品和服务，以预防和治疗农场动物和宠物的疾病，为农民、宠物主人、兽医、利益相关者和整个社会创造价值。此前，Doyle先生于2004年6月至2020年10月担任OptiNose, Inc.（Nasdaq：OPTN）（一家专注于耳鼻喉（ENT）和过敏专家治疗的患者的制药公司）和Zoetis, Inc.（纽约证券交易所股票代码：ZTS）的董事会成员，Zoetis, Inc.（纽约证券交易所股票代码：ZTS），一家领先的动物保健公司，致力于支持其客户及其业务，2015年2月至2016年3月和Minerva Neurosciences, Inc.(Nasdaq：NERV是一家临床阶段的生物制药公司，专注于开发治疗中枢神经系统疾病的疗法，从2017年11月到2023年5月。他持有Massachusetts Institute of Technology的材料科学与工程学士学位，以及Harvard Business School的工商管理硕士学位。
William F. Doyle,has served as Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of Board of Directors since 2004. Mr. Doyle has been the managing director of WFD Ventures LLC, a private venture capital firm he co-founded, since 2002. Prior to 2002, Mr. Doyle was a member of Johnson & Johnson's Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and Acquisitions. While at Johnson & Johnson, Mr. Doyle was also chairman of the Medical Devices Research and Development Council, and Worldwide president of Biosense-Webster, Inc. and a member of the board of directors of Cordis Corporation and Johnson & Johnson Development Corporation, Johnson & Johnson's venture capital subsidiary. Earlier in his career, Mr. Doyle was a management consultant in the healthcare group of McKinsey & Company. Mr. Doyle is also a member of the Governing Board of the Pershing Square Sohn Cancer Research Alliance. From 2014 to 2016 he was a member of the investment team at Pershing Square Capital Management L.P., a private investment firm and from November 2016 to January 2021, Mr.Doyle served as the Executive Chairman of BlinkHealth LLC, which has developed a pharmacy-as-a-service, e-commerce platform. Mr. Doyle has been a director of Elanco Animal Health, Inc. since 2020 and ProKidney, Inc. since 2022. Mr. Doyle previously served as a director of Optinose, Inc., a commercial-stage specialty pharmaceuticals company, from 2004 to 2020 and director of Minerva Neurosciences, Inc., from 2017 to 2023. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. Mr. Doyle serves on Harvard Business School's Board of Dean's Advisors and MIT's Institute of Medical Engineering & Science Visiting Committee. - William F. Doyle，自交易完成以来，他一直担任ProKidney Corp. GP Limited（“GP”）（“GP董事会”）的董事会成员。Doyle先生自2022年1月起担任ProKidney GP Limited（“Legacy GP”）（“Legacy GP董事会”）的董事会成员，并自2022年1月起担任ProKidney（前身为RegenMed （Cayman） Ltd. （d/b/a inRegen））（“ProKidney- ky”）（“ProKidney- ky董事会”）的董事会成员。他自2016年5月起担任NovoCure Limited（Nasdaq：NVCR）的执行主席，这是一家商业阶段的肿瘤学公司，目前正在开发肿瘤治疗领域，一种实体肿瘤癌症的新疗法（“NovoCure”），自2004年2月起担任NovoCure董事会成员。2002年6月以来，他一直担任WFD Ventures LLC（他共同创立的私人风险投资公司）的董事总经理。在此之前，他是Johnson & Johnson的医疗器械和诊断集团运营委员会的成员，从1994年到1999年担任许可和收购副总裁。在Johnson & Johnson任职期间，Doyle先生也是Biosense-Webster, Inc.的全球总裁，Johnson & Johnson Development Corporation （Johnson & Johnson的风险投资子公司）的董事会成员。Doyle先生自2020年10月起担任Elanco Animal Health, Inc.（纽约证券交易所代码：ELAN）的董事会成员，Elanco Animal Health, Inc.是动物健康领域的全球领导者，致力于创新和提供产品和服务，以预防和治疗农场动物和宠物的疾病，为农民、宠物主人、兽医、利益相关者和整个社会创造价值。此前，Doyle先生于2004年6月至2020年10月担任OptiNose, Inc.（Nasdaq：OPTN）（一家专注于耳鼻喉（ENT）和过敏专家治疗的患者的制药公司）和Zoetis, Inc.（纽约证券交易所股票代码：ZTS）的董事会成员，Zoetis, Inc.（纽约证券交易所股票代码：ZTS），一家领先的动物保健公司，致力于支持其客户及其业务，2015年2月至2016年3月和Minerva Neurosciences, Inc.(Nasdaq：NERV是一家临床阶段的生物制药公司，专注于开发治疗中枢神经系统疾病的疗法，从2017年11月到2023年5月。他持有Massachusetts Institute of Technology的材料科学与工程学士学位，以及Harvard Business School的工商管理硕士学位。
- William F. Doyle,has served as Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of Board of Directors since 2004. Mr. Doyle has been the managing director of WFD Ventures LLC, a private venture capital firm he co-founded, since 2002. Prior to 2002, Mr. Doyle was a member of Johnson & Johnson's Medical Devices and Diagnostics Group Operating Committee and was Vice President, Licensing and Acquisitions. While at Johnson & Johnson, Mr. Doyle was also chairman of the Medical Devices Research and Development Council, and Worldwide president of Biosense-Webster, Inc. and a member of the board of directors of Cordis Corporation and Johnson & Johnson Development Corporation, Johnson & Johnson's venture capital subsidiary. Earlier in his career, Mr. Doyle was a management consultant in the healthcare group of McKinsey & Company. Mr. Doyle is also a member of the Governing Board of the Pershing Square Sohn Cancer Research Alliance. From 2014 to 2016 he was a member of the investment team at Pershing Square Capital Management L.P., a private investment firm and from November 2016 to January 2021, Mr.Doyle served as the Executive Chairman of BlinkHealth LLC, which has developed a pharmacy-as-a-service, e-commerce platform. Mr. Doyle has been a director of Elanco Animal Health, Inc. since 2020 and ProKidney, Inc. since 2022. Mr. Doyle previously served as a director of Optinose, Inc., a commercial-stage specialty pharmaceuticals company, from 2004 to 2020 and director of Minerva Neurosciences, Inc., from 2017 to 2023. Mr. Doyle holds an S.B. in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. Mr. Doyle serves on Harvard Business School's Board of Dean's Advisors and MIT's Institute of Medical Engineering & Science Visiting Committee.
- David Hung
-
David Hung，自2018年4月起担任生物技术公司Nuvation Bio Inc.的创始人、总裁、首席执行官兼董事。洪博士曾于2017年4月至2018年2月担任生物制药公司Axovant Sciences，Inc.的首席执行官和董事。作为生物制药公司Medivation Inc.（“Medivation”）的创始人，他曾于2004年至2016年担任Medivation的总裁、首席执行官和董事。从1998年到2001年，洪博士受雇于私营医疗设备公司ProDuct Health，Inc.，于1998年至1999年担任首席科学官，并于1999年至2001年担任总裁兼首席执行官和董事。
David Hung,is the founder, President, Chief Executive Officer and Director of Nuvation Bio Inc., a biotech company, since April 2018. Dr. Hung was previously Chief Executive Officer and a Director of Axovant Sciences, Inc., a biopharmaceutical company, from April 2017 to February 2018. As a founder of Medivation Inc. ("Medivation"), a biopharmaceutical company, he served as President, Chief Executive Officer and a Director of Medivation from 2004 to 2016. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer from 1998 to 1999 and as President and Chief Executive Officer and Director from 1999 to 2001. - David Hung，自2018年4月起担任生物技术公司Nuvation Bio Inc.的创始人、总裁、首席执行官兼董事。洪博士曾于2017年4月至2018年2月担任生物制药公司Axovant Sciences，Inc.的首席执行官和董事。作为生物制药公司Medivation Inc.（“Medivation”）的创始人，他曾于2004年至2016年担任Medivation的总裁、首席执行官和董事。从1998年到2001年，洪博士受雇于私营医疗设备公司ProDuct Health，Inc.，于1998年至1999年担任首席科学官，并于1999年至2001年担任总裁兼首席执行官和董事。
- David Hung,is the founder, President, Chief Executive Officer and Director of Nuvation Bio Inc., a biotech company, since April 2018. Dr. Hung was previously Chief Executive Officer and a Director of Axovant Sciences, Inc., a biopharmaceutical company, from April 2017 to February 2018. As a founder of Medivation Inc. ("Medivation"), a biopharmaceutical company, he served as President, Chief Executive Officer and a Director of Medivation from 2004 to 2016. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer from 1998 to 1999 and as President and Chief Executive Officer and Director from 1999 to 2001.
- Allyson Ocean
-
Allyson Ocean，于2023年2月当选为董事会成员。Ocean博士目前是康奈尔大学威尔医学院的临床医学教授，自2004年以来，她一直担任该学院的多个职位。Ocean博士目前还担任纽约长老会医院/威尔康乃尔医疗中心的内科肿瘤学家和胃肠道肿瘤学主治医师，以及Jay Monahan胃肠道健康中心的内科肿瘤学家。
Allyson Ocean,was elected to Board in February 2023. Dr. Ocean is currently a Professor of Clinical Medicine at the Weill Medical College of Cornell University, where she has held various positions since 2004. Dr. Ocean also currently serves as a medical oncologist and attending physician in gastrointestinal oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, as well as a medical oncologist at The Jay Monahan Center for Gastrointestinal Health. - Allyson Ocean，于2023年2月当选为董事会成员。Ocean博士目前是康奈尔大学威尔医学院的临床医学教授，自2004年以来，她一直担任该学院的多个职位。Ocean博士目前还担任纽约长老会医院/威尔康乃尔医疗中心的内科肿瘤学家和胃肠道肿瘤学主治医师，以及Jay Monahan胃肠道健康中心的内科肿瘤学家。
- Allyson Ocean,was elected to Board in February 2023. Dr. Ocean is currently a Professor of Clinical Medicine at the Weill Medical College of Cornell University, where she has held various positions since 2004. Dr. Ocean also currently serves as a medical oncologist and attending physician in gastrointestinal oncology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, as well as a medical oncologist at The Jay Monahan Center for Gastrointestinal Health.
- Kristin Stafford
-
克里斯汀·斯塔福德，于2023年3月当选为董事会成员。Stafford女士现任Royalty Pharma PLC高级副总裁兼首席会计官，自2018年12月起担任该职位。在担任此职位之前，她曾于2016年至2018年担任Royalty Pharma财务副总裁以及皇家制药的关联公司BioPharma Credit PLC的首席财务官。Stafford女士是注册会计师，拥有索诺玛州立大学工商管理理学学士学位。
Kristin Stafford,was elected to Board in March 2023. Ms. Stafford is currently Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, a position she has held since December 2018. Prior to this position, she served as Vice President, Finance of Royalty Pharma and Chief Financial Officer of BioPharma Credit plc, an affiliate of Royal Pharma, from 2016 to 2018. Ms. Stafford is a Certified Public Accountant and holds a bachelor of science degree in business administration from Sonoma State University. - 克里斯汀·斯塔福德，于2023年3月当选为董事会成员。Stafford女士现任Royalty Pharma PLC高级副总裁兼首席会计官，自2018年12月起担任该职位。在担任此职位之前，她曾于2016年至2018年担任Royalty Pharma财务副总裁以及皇家制药的关联公司BioPharma Credit PLC的首席财务官。Stafford女士是注册会计师，拥有索诺玛州立大学工商管理理学学士学位。
- Kristin Stafford,was elected to Board in March 2023. Ms. Stafford is currently Senior Vice President, Chief Accounting Officer for Royalty Pharma plc, a position she has held since December 2018. Prior to this position, she served as Vice President, Finance of Royalty Pharma and Chief Financial Officer of BioPharma Credit plc, an affiliate of Royal Pharma, from 2016 to 2018. Ms. Stafford is a Certified Public Accountant and holds a bachelor of science degree in business administration from Sonoma State University.
- Jeryl Hilleman
-
Jeryl Hilleman从2008年1月开始担任Minerva Neurosciences, Inc.首席财务官。加入阿米瑞斯公司（Amyris）以前，从1997年到2007年6月，她担任赛美科技有限公司（Symyx Technologies, Inc.）的执行副总裁和首席财务官，这是一家研发基础设施公司，其为技术公司提供科学软件与研究服务。加入赛美科技以前，Hilleman女士在两家生物技术公司任职，从1992年到1997年，在美国杰龙生物医药公司（Geron Corporation）担任财务部副总裁，这是一家生物医药公司，从1987年到1992年，担任Cytel Corporation的首席财务官，这是一家生物医药公司。 Hilleman女士在布朗大学（M Brown University）获得历史学文学学士学位，并在沃顿商学院（Wharton Graduate School of Business）获得工商管理硕士学位。
Jeryl Hilleman,has served as a member of board of directors since April 2019, including as Chairperson since July 2020. Ms. Hilleman previously served as Chief Financial Officer of several publicly held healthcare companies, including most recently at Intersect ENT, Inc., a medical device company subsequently acquired by Medtronic plc, from June 2014 to December 2019. Prior to joining Intersect ENT, Ms. Hilleman was Chief Financial Officer of publicly held Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals, Inc., Amyris, Inc., a renewable products company, and Symyx Technologies, Inc., a software and instruments company acquired by Accelrys, Inc. She has served on the boards of directors of NovoCure Limited, a publicly held oncology company, since July 2018, SI-Bone, Inc., a publicly held medical device company, since December 2019, and HilleVax, Inc., a publicly held biopharmaceutical company, since April 2021. In addition, she previously served on the boards of directors of Xenoport Inc., a publicly held biotechnology company, from January 2005 to July 2016, Talis Biomedical Corporation, a publicly held diagnostics company, from April 2021 to June 2022, Minerva Neurosciences, Inc., a publicly held biotechnology company, from July 2018 to August 2024, and Cutera, Inc., a publicly held medical device company, from July 2024 to February 2025. Ms. Hilleman holds an A.B. in History from Brown University and an M.B.A. from The Wharton School at the University of Pennsylvania. - Jeryl Hilleman从2008年1月开始担任Minerva Neurosciences, Inc.首席财务官。加入阿米瑞斯公司（Amyris）以前，从1997年到2007年6月，她担任赛美科技有限公司（Symyx Technologies, Inc.）的执行副总裁和首席财务官，这是一家研发基础设施公司，其为技术公司提供科学软件与研究服务。加入赛美科技以前，Hilleman女士在两家生物技术公司任职，从1992年到1997年，在美国杰龙生物医药公司（Geron Corporation）担任财务部副总裁，这是一家生物医药公司，从1987年到1992年，担任Cytel Corporation的首席财务官，这是一家生物医药公司。 Hilleman女士在布朗大学（M Brown University）获得历史学文学学士学位，并在沃顿商学院（Wharton Graduate School of Business）获得工商管理硕士学位。
- Jeryl Hilleman,has served as a member of board of directors since April 2019, including as Chairperson since July 2020. Ms. Hilleman previously served as Chief Financial Officer of several publicly held healthcare companies, including most recently at Intersect ENT, Inc., a medical device company subsequently acquired by Medtronic plc, from June 2014 to December 2019. Prior to joining Intersect ENT, Ms. Hilleman was Chief Financial Officer of publicly held Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt Pharmaceuticals, Inc., Amyris, Inc., a renewable products company, and Symyx Technologies, Inc., a software and instruments company acquired by Accelrys, Inc. She has served on the boards of directors of NovoCure Limited, a publicly held oncology company, since July 2018, SI-Bone, Inc., a publicly held medical device company, since December 2019, and HilleVax, Inc., a publicly held biopharmaceutical company, since April 2021. In addition, she previously served on the boards of directors of Xenoport Inc., a publicly held biotechnology company, from January 2005 to July 2016, Talis Biomedical Corporation, a publicly held diagnostics company, from April 2021 to June 2022, Minerva Neurosciences, Inc., a publicly held biotechnology company, from July 2018 to August 2024, and Cutera, Inc., a publicly held medical device company, from July 2024 to February 2025. Ms. Hilleman holds an A.B. in History from Brown University and an M.B.A. from The Wharton School at the University of Pennsylvania.
- David Hung
-
David Hung，担任ARYA Sciences Acquisition Corp.的董事。Hung博士最近担任Axovant Biosciences Inc.的首席执行官(从2017年4月到2018年2月辞职)。2006年5月以来，他担任Acer Therapeutics Inc.董事。2004年12月以来，他担任Medivation, Inc.的总裁、首席执行官和董事。2003年9月Medivation, Inc.的子公司Medivation Neurology, Inc.成立以来，他担任其总裁、首席执行官和董事会成员。从1998年到2001年，他曾在ProDuct Health, Inc.（私有医疗设备公司）任职，并担任首席科学家（1998年到1999年）和总裁兼首席执行官（1999年到2001年）。从1996年到1998年,Hung在喀戎公司担任各种高级职位,包括领导发现和发展的副总裁和新项目的副总裁。从2001年12月到2001年1月，他担任Cytyc Health Corporation的顾问。获得的加州大学旧金山,医学院的医学博士学位,以及哈佛大学的生物学AB学位。是一个上市的生物制药公司（活跃于临床药物开发）的首席执行官。
David Hung has served as a Director since May 2006. Dr. Hung has served as the president, chief executive officer and as a director of Medivation, Inc. since December 2004. Dr. Hung also has served as the president and chief executive officer, and member of the board of directors, of Medivation, Inc.'s subsidiary, Medivation Neurology, Inc., since its inception in September 2003. From 1998 until 2001 Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999), and as president and chief executive officer (1999-2001). From December 2001 to January 2003 Dr. Hung served as a consultant to Cytyc Health Corporation. Dr. Hung received his M.D. from the University of California at San Francisco, and his A.B. in biology and organic chemistry from Harvard College. As the chief executive officer of a public biopharmaceutical company actively engaged in clinical drug development, Dr. Hung offers extensive experience in numerous aspects of managing a pre-commercialization drug development company, including strategic planning, clinical development, and strategic partnering. - David Hung，担任ARYA Sciences Acquisition Corp.的董事。Hung博士最近担任Axovant Biosciences Inc.的首席执行官(从2017年4月到2018年2月辞职)。2006年5月以来，他担任Acer Therapeutics Inc.董事。2004年12月以来，他担任Medivation, Inc.的总裁、首席执行官和董事。2003年9月Medivation, Inc.的子公司Medivation Neurology, Inc.成立以来，他担任其总裁、首席执行官和董事会成员。从1998年到2001年，他曾在ProDuct Health, Inc.（私有医疗设备公司）任职，并担任首席科学家（1998年到1999年）和总裁兼首席执行官（1999年到2001年）。从1996年到1998年,Hung在喀戎公司担任各种高级职位,包括领导发现和发展的副总裁和新项目的副总裁。从2001年12月到2001年1月，他担任Cytyc Health Corporation的顾问。获得的加州大学旧金山,医学院的医学博士学位,以及哈佛大学的生物学AB学位。是一个上市的生物制药公司（活跃于临床药物开发）的首席执行官。
- David Hung has served as a Director since May 2006. Dr. Hung has served as the president, chief executive officer and as a director of Medivation, Inc. since December 2004. Dr. Hung also has served as the president and chief executive officer, and member of the board of directors, of Medivation, Inc.'s subsidiary, Medivation Neurology, Inc., since its inception in September 2003. From 1998 until 2001 Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999), and as president and chief executive officer (1999-2001). From December 2001 to January 2003 Dr. Hung served as a consultant to Cytyc Health Corporation. Dr. Hung received his M.D. from the University of California at San Francisco, and his A.B. in biology and organic chemistry from Harvard College. As the chief executive officer of a public biopharmaceutical company actively engaged in clinical drug development, Dr. Hung offers extensive experience in numerous aspects of managing a pre-commercialization drug development company, including strategic planning, clinical development, and strategic partnering.
高管简历
中英对照 | 中文 | 英文- Nicolas Leupin
Nicolas Leupin，自2019年9月起担任Molecular Partners AG的首席医疗官。Leupin博士是一名肿瘤内科医师，在药物开发方面有着成功的记录，最近在2016年至2019年担任argenx的首席医疗官，这是一家临床阶段的生物技术公司，开发基于抗体的疗法，用于治疗严重的自身免疫性疾病和癌症。在首席医疗官这一职位上，他领导了公司的全球临床战略和执行，成功地支持了公司向晚期临床公司的转型，并负责将临床前假设转化为创新的概念验证临床试验。在加入argenx之前，Leupin博士在Celgene担任越来越重要的角色，他支持淋巴瘤和多发性骨髓瘤的几种候选药物的临床开发，并在欧洲和美国提交了监管文件。
Nicolas Leupin,has served as Chief Medical Officer since January 2024. Dr. Leupin previously served as Chief Medical Officer of Molecular Partners AG since August 2019. Prior to that Dr. Leupin served as Chief Medical Officer of argenx from 2016. Dr. Leupin holds an M.D. from the University of Bern, an M.B.A. from Jones International University and a Ph.D. from the Université Bourgogne-Franche-Comté.- Nicolas Leupin，自2019年9月起担任Molecular Partners AG的首席医疗官。Leupin博士是一名肿瘤内科医师，在药物开发方面有着成功的记录，最近在2016年至2019年担任argenx的首席医疗官，这是一家临床阶段的生物技术公司，开发基于抗体的疗法，用于治疗严重的自身免疫性疾病和癌症。在首席医疗官这一职位上，他领导了公司的全球临床战略和执行，成功地支持了公司向晚期临床公司的转型，并负责将临床前假设转化为创新的概念验证临床试验。在加入argenx之前，Leupin博士在Celgene担任越来越重要的角色，他支持淋巴瘤和多发性骨髓瘤的几种候选药物的临床开发，并在欧洲和美国提交了监管文件。
- Nicolas Leupin,has served as Chief Medical Officer since January 2024. Dr. Leupin previously served as Chief Medical Officer of Molecular Partners AG since August 2019. Prior to that Dr. Leupin served as Chief Medical Officer of argenx from 2016. Dr. Leupin holds an M.D. from the University of Bern, an M.B.A. from Jones International University and a Ph.D. from the Université Bourgogne-Franche-Comté.
- Barak Ben Arye
Barak Ben Arye，自2022年4月起担任总法律顾问，在此之前，他曾担任副总裁，自2019年6月起担任欧洲、中东和非洲法律顾问，自2018年加入Novocure Limited以来担任欧洲、中东和非洲法律顾问高级董事。Ben-Arye先生曾于2014年至2018年担任Gaash Business and Agriculture，Cooperative Agriculture Society Ltd.的首席执行官，该协会是一家从事工业、农业、商业、房地产和旅游业的以色列合作协会。在加入Gaash之前，他曾于2005年至2013年在特拉维夫的一家国际律师事务所Raved，Magriso，Benkel & Co.（后并入Shibolet & Co.）工作，最后担任该事务所高科技和生命科学部门的合伙人。Ben-Arye先生获得了以色列Reichman大学（IDC Herzliya）的法学学士学位和工商管理学士学位。
Barak Ben Arye,has been General Counsel since April 2022 and prior to that was Vice President, EMEA Counsel since June 2019 and Senior Director, EMEA Counsel since joining Novocure Limited in 2018. Mr. Ben-Arye served as the Chief Executive Officer of Gaash Business and Agriculture, Cooperative Agricultural Society Ltd., an Israeli cooperative association engaged in industry, agriculture, commerce, real estate and tourism, from 2014 to 2018. Prior to joining Gaash, he worked for Raved, Magriso, Benkel & Co., an international law firm in Tel Aviv (later merged into Shibolet & Co.) from 2005 to 2013, last serving as a partner in the firm's hi-tech and life science department. Mr. Ben-Arye earned his Bachelor of Laws and his Bachelor of Business Administration from Reichman University (IDC Herzliya) in Israel.- Barak Ben Arye，自2022年4月起担任总法律顾问，在此之前，他曾担任副总裁，自2019年6月起担任欧洲、中东和非洲法律顾问，自2018年加入Novocure Limited以来担任欧洲、中东和非洲法律顾问高级董事。Ben-Arye先生曾于2014年至2018年担任Gaash Business and Agriculture，Cooperative Agriculture Society Ltd.的首席执行官，该协会是一家从事工业、农业、商业、房地产和旅游业的以色列合作协会。在加入Gaash之前，他曾于2005年至2013年在特拉维夫的一家国际律师事务所Raved，Magriso，Benkel & Co.（后并入Shibolet & Co.）工作，最后担任该事务所高科技和生命科学部门的合伙人。Ben-Arye先生获得了以色列Reichman大学（IDC Herzliya）的法学学士学位和工商管理学士学位。
- Barak Ben Arye,has been General Counsel since April 2022 and prior to that was Vice President, EMEA Counsel since June 2019 and Senior Director, EMEA Counsel since joining Novocure Limited in 2018. Mr. Ben-Arye served as the Chief Executive Officer of Gaash Business and Agriculture, Cooperative Agricultural Society Ltd., an Israeli cooperative association engaged in industry, agriculture, commerce, real estate and tourism, from 2014 to 2018. Prior to joining Gaash, he worked for Raved, Magriso, Benkel & Co., an international law firm in Tel Aviv (later merged into Shibolet & Co.) from 2005 to 2013, last serving as a partner in the firm's hi-tech and life science department. Mr. Ben-Arye earned his Bachelor of Laws and his Bachelor of Business Administration from Reichman University (IDC Herzliya) in Israel.
- Francis Leonard
Francis Leonard，自2024年1月起担任执行副总裁兼Novocure肿瘤学总裁。Leonard先生于2010年加入Novocure，最近担任CNS癌症美国区总裁。在加入Novocure之前，Leonard先生是一位专注于高影响力医疗技术的风险资本投资者。伦纳德先生拥有哈佛大学的学士学位和伦敦政治经济学院的硕士学位。
Francis Leonard,has been Executive Vice President, President Novocure Oncology since January 2024. Mr. Leonard joined Novocure in 2010, and most recently served as President, CNS Cancers U.S. Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.- Francis Leonard，自2024年1月起担任执行副总裁兼Novocure肿瘤学总裁。Leonard先生于2010年加入Novocure，最近担任CNS癌症美国区总裁。在加入Novocure之前，Leonard先生是一位专注于高影响力医疗技术的风险资本投资者。伦纳德先生拥有哈佛大学的学士学位和伦敦政治经济学院的硕士学位。
- Francis Leonard,has been Executive Vice President, President Novocure Oncology since January 2024. Mr. Leonard joined Novocure in 2010, and most recently served as President, CNS Cancers U.S. Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.
- Mukund Paravasthu
Mukund Paravasthu，自2024年10月起担任首席运营官。Paravasthu先生此前于2022年4月开始担任Novocure的产品开发高级副总裁。Paravasthu先生于2020年5月加入Novocure Limited，担任产品开发副总裁。在加入Novocure之前，Paravasthu先生自2007年起在强生的骨科专营权Depuy Synthes担任过多个领导职务。Paravasthu先生拥有俄克拉何马大学电气工程硕士学位和印度安纳马莱大学电气和电子工程学士学位。
Mukund Paravasthu,has been Chief Operating Officer since October 2024. Mr. Paravasthu previously served as Novocure's Senior Vice President of Product Development beginning in April 2022. Mr. Paravasthu joined Novocure Limited in May 2020 as Vice President of Product Development. Before joining Novocure, Mr. Paravasthu held several leadership roles at Johnson & Johnson's orthopedic franchise, DePuy Synthes, from 2007. Mr. Paravasthu holds a Master's degree in Electrical Engineering from the University of Oklahoma and a Bachelors in Electrical and Electronics Engineering from Annamalai University, India.- Mukund Paravasthu，自2024年10月起担任首席运营官。Paravasthu先生此前于2022年4月开始担任Novocure的产品开发高级副总裁。Paravasthu先生于2020年5月加入Novocure Limited，担任产品开发副总裁。在加入Novocure之前，Paravasthu先生自2007年起在强生的骨科专营权Depuy Synthes担任过多个领导职务。Paravasthu先生拥有俄克拉何马大学电气工程硕士学位和印度安纳马莱大学电气和电子工程学士学位。
- Mukund Paravasthu,has been Chief Operating Officer since October 2024. Mr. Paravasthu previously served as Novocure's Senior Vice President of Product Development beginning in April 2022. Mr. Paravasthu joined Novocure Limited in May 2020 as Vice President of Product Development. Before joining Novocure, Mr. Paravasthu held several leadership roles at Johnson & Johnson's orthopedic franchise, DePuy Synthes, from 2007. Mr. Paravasthu holds a Master's degree in Electrical Engineering from the University of Oklahoma and a Bachelors in Electrical and Electronics Engineering from Annamalai University, India.
- Michael Puri
Michael Puri，自2023年9月起担任首席人力资源官。Puri先生此前曾在CSL有限公司担任副总裁兼人力资源整合主管，此前该公司收购了Vifor Pharma，并于2015年至2022年担任首席人力资源官。2013年至2015年，他还在国际光学零售领导者GrandVision担任首席人力资源官。普里先生还曾在Staples，Inc.和全球生物制药公司UCB S.A.担任领导职务。他在南特大学获得经济学学士学位，在格勒诺布尔商学院获得战略营销硕士学位。
Michael Puri,has served as Chief Human Resources Officer since September 2023. Mr. Puri previously served as Vice President, HR Integration lead at CSL Limited, following the company's acquisition of Vifor Pharma, where he served as Chief Human Resources Officer from 2015 to 2022. He also served as Chief Human Resources Officer at GrandVision, an international leader in optical retailing, from 2013 to 2015. Mr. Puri has also held leadership positions at Staples, Inc. and UCB S.A., a global biopharma company. He earned his bachelor's degree in economics from the University of Nantes and his master's degree in strategic marketing from the Grenoble Business School.- Michael Puri，自2023年9月起担任首席人力资源官。Puri先生此前曾在CSL有限公司担任副总裁兼人力资源整合主管，此前该公司收购了Vifor Pharma，并于2015年至2022年担任首席人力资源官。2013年至2015年，他还在国际光学零售领导者GrandVision担任首席人力资源官。普里先生还曾在Staples，Inc.和全球生物制药公司UCB S.A.担任领导职务。他在南特大学获得经济学学士学位，在格勒诺布尔商学院获得战略营销硕士学位。
- Michael Puri,has served as Chief Human Resources Officer since September 2023. Mr. Puri previously served as Vice President, HR Integration lead at CSL Limited, following the company's acquisition of Vifor Pharma, where he served as Chief Human Resources Officer from 2015 to 2022. He also served as Chief Human Resources Officer at GrandVision, an international leader in optical retailing, from 2013 to 2015. Mr. Puri has also held leadership positions at Staples, Inc. and UCB S.A., a global biopharma company. He earned his bachelor's degree in economics from the University of Nantes and his master's degree in strategic marketing from the Grenoble Business School.
- Uri Weinberg
Uri Weinberg自2023年1月起担任首席创新官，负责扩大肿瘤治疗领域疗法的创新潜力。自2008年加入Novocure以来，他在公司任职期间曾担任多个职位，最近一次自2020年起担任首席科学官一职。温伯格博士拥有以色列理工学院的医学博士学位。
Uri Weinberg,has served as Chief Innovation Officer since January 2023, where he is responsible for expanding the innovative potential of Tumor Treating Fields therapy. Since joining Novocure in 2008, he has held several positions throughout his tenure with the Company and most recently held the position of Chief Science Officer since 2020. Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.- Uri Weinberg自2023年1月起担任首席创新官，负责扩大肿瘤治疗领域疗法的创新潜力。自2008年加入Novocure以来，他在公司任职期间曾担任多个职位，最近一次自2020年起担任首席科学官一职。温伯格博士拥有以色列理工学院的医学博士学位。
- Uri Weinberg,has served as Chief Innovation Officer since January 2023, where he is responsible for expanding the innovative potential of Tumor Treating Fields therapy. Since joining Novocure in 2008, he has held several positions throughout his tenure with the Company and most recently held the position of Chief Science Officer since 2020. Dr. Weinberg holds an M.D. Ph.D. from the Technion – Israel Institute of Technology.
- Francis Leonard
Frank Leonard，于2025年6月被任命为公司总裁。他负责自2024年1月以来由他领导的Novocure的全球业务运营，并负责销售、市场营销、外勤医疗事务、患者体验、公共事务、市场准入以及产品和产品组合战略职能。Leonard先生此前于2022年10月开始领导Novocure Limited美国业务。Leonard先生于2020年9月至2022年9月担任公司首席开发官，负责工程、产品开发、业务发展以及公司创新平台的整体战略和运营领导。他于2010年加入公司，为公司的商业发布做准备，并担任过建立公司财务、报销和业务发展职能的各种职务。在加入公司之前，Leonard先生是一位风险资本投资者，专注于高影响力医疗技术公司，包括Novocure。自2023年以来，他一直担任医疗器械制造商协会（MDMA）的理事。伦纳德先生于2001年获得哈佛大学的A.B.学位，并于2004年获得伦敦政治经济学院的硕士学位。
Francis Leonard,has been Executive Vice President, President Novocure Oncology since January 2024. Mr. Leonard joined Novocure in 2010, and most recently served as President, CNS Cancers U.S. Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.- Frank Leonard，于2025年6月被任命为公司总裁。他负责自2024年1月以来由他领导的Novocure的全球业务运营，并负责销售、市场营销、外勤医疗事务、患者体验、公共事务、市场准入以及产品和产品组合战略职能。Leonard先生此前于2022年10月开始领导Novocure Limited美国业务。Leonard先生于2020年9月至2022年9月担任公司首席开发官，负责工程、产品开发、业务发展以及公司创新平台的整体战略和运营领导。他于2010年加入公司，为公司的商业发布做准备，并担任过建立公司财务、报销和业务发展职能的各种职务。在加入公司之前，Leonard先生是一位风险资本投资者，专注于高影响力医疗技术公司，包括Novocure。自2023年以来，他一直担任医疗器械制造商协会（MDMA）的理事。伦纳德先生于2001年获得哈佛大学的A.B.学位，并于2004年获得伦敦政治经济学院的硕士学位。
- Francis Leonard,has been Executive Vice President, President Novocure Oncology since January 2024. Mr. Leonard joined Novocure in 2010, and most recently served as President, CNS Cancers U.S. Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.
- Christoph Brackmann
Christoph Brackmann，自2025年1月1日起担任首席财务官。Brackmann先生于2024年10月加入Novocure Limited，担任首席财务官特别顾问。在加入Novocure之前，Brackmann先生于2019年10月至2024年6月期间担任Moderna公司财务高级副总裁。Brackmann先生于2003年在米兰SDA博科尼管理学院获得工商管理硕士学位，并拥有曼海姆大学商业和经济学学士学位。
Christoph Brackmann,has been Chief Financial Officer since January 1, 2025. Mr. Brackmann joined Novocure Limited as a Special Advisor to the Chief Financial Officer in October 2024. Prior to joining Novocure, Mr. Brackmann served as the Senior Vice President of Finance at Moderna Inc. from October 2019 to June 2024. Mr. Brackmann earned his Master of Business Administration from the SDA Bocconi School of Management, Milan in 2003 and holds a bachelors degree in Business and Economics from the University of Mannheim.- Christoph Brackmann，自2025年1月1日起担任首席财务官。Brackmann先生于2024年10月加入Novocure Limited，担任首席财务官特别顾问。在加入Novocure之前，Brackmann先生于2019年10月至2024年6月期间担任Moderna公司财务高级副总裁。Brackmann先生于2003年在米兰SDA博科尼管理学院获得工商管理硕士学位，并拥有曼海姆大学商业和经济学学士学位。
- Christoph Brackmann,has been Chief Financial Officer since January 1, 2025. Mr. Brackmann joined Novocure Limited as a Special Advisor to the Chief Financial Officer in October 2024. Prior to joining Novocure, Mr. Brackmann served as the Senior Vice President of Finance at Moderna Inc. from October 2019 to June 2024. Mr. Brackmann earned his Master of Business Administration from the SDA Bocconi School of Management, Milan in 2003 and holds a bachelors degree in Business and Economics from the University of Mannheim.